[Treatment of rheumatoid arthritis. Open parallel study with the non-steroidal antirheumatics piroxicam and diclofenac].
Piroxicam and diclofenac were compared for 4 weeks in an open parallel study in 20 rheumatoid arthritis patients each. Both preparations showed good efficacy and were well tolerated, piroxicam appearing to be slightly superior in both respects. Piroxicam exercised a significant action on the inflammation-specific parameters (reduction of BSR by 6.15 mm maximum and of the alpha 2-globulin fraction by 0.75%), whereas diclofenac did not. Another advantage of piroxicam is its low effective dosage level achieved by a single daily dose.